Language

Pulmonary Research

Innovative Therapies Close to Home

MultiCare Pulmonary Specialists is a multi-physician group located in Tacoma, WA. The site employs an experienced research team comprised of board certified Pulmonologists, Study Coordinators, and an Administrative Assistant. The site is conveniently located near three hospitals and all clinical research is done on site. In addition, the site has a comprehensive patient database that is connected to all MultiCare facilities.

Pulmonary studies include the following therapeutic areas:

  • Asthma
  • Allergy & Allergic Rhinitis
  • COPD
  • Smoking Cessation
  • Sleep Disorders
  • Cystic Fibrosis
  • Bronchiectasis

Principal Investigator:

Sub-Investigators:

Pulmonary Studies Accepting Participants

Adults 

COPD

Ethos

Study Number: PT010005-01—A randomized, double-blind, multi-center, parallel group study to assess the efficacy and safety of PT010 relative to PT003 and PT009 on COPD exacerbations over a 52-week treatment period in subjects with moderate to very severe COPD.

Study Info

Principal Investigator(s): Stephen Ryan, MD

Study Coordinator: Juanita Baker, [email protected], 253-403-0366 


Vigito

Study Number: 1237.35A randomized, double-blind, active-controlled parallel group study to evaluate the impact of once daily treatment with orally inhaled tiotropium + olodaterol (5ug/5ug) fixed dose combination compared with tiotropium (5ug) on long term outcomes in patients with chronic obstructive pulmonary disease (COPD) and moderate (GOLD stage ll) lung function impairment.

Principal Investigator(s): Stephen Ryan, MD

Study Coordinator: Juanita Baker, [email protected], 253-403-0366


Energito

Study Number: 1237.63—A randomized, double-blind, double-dummy, active-controlled, multi-center, parallel group study to show the superiority in lung function of 12 weeks once daily treatment with orally inhaled tiotropium+olodaterol fixed dose combination delivered by the Respimat inhaler vs. 12 weeks twice daily treatment with orally inhaled fluticasone propionate+salmeterol fixed dose combination delivered by the Diskus in patients with chronic obstructive pulmonary disease (COPD).

Principal Investigator(s): Stephen Ryan, MD

Study Coordinator: Jami Smith, [email protected], 253-403-0389


Chiesi

Study NumberCCD-0599AA3-02—A 6-week, multi-center, randomized, double-blind, placebo-and active-controlled, parallel group, dose-ranging study to evaluate the efficacy and safety of 4 doses of CHF 5259 pMDI (HFA Glycopyrronium Bromide via Pressurized Metered Dose Inhaler) in subjects with chronic obstructive pulmonary disease (COPD).  

Study Info

Principal Investigator(s): Stephen Ryan, MD

Study Coordinator: Jami Smith, [email protected], 253-403-0389

Asthma

ANDHI

Study NumberD3250C00045—A multi-center, randomized, double-blind, parallel group, placebo-controlled, Phase 3b study to evaluate the safety and efficacy of the Benralizumab 30 mg sc in patients with severe asthma uncontrolled on standard of care treatment.

Principal Investigator(s): Stephen Ryan, MD

Study Coordinator: Jami Smith, [email protected], 253-403-0389

Influenza A

Visterra

Study NumberVIS410-203—A Phase 2b, multi-center, randomized, double-blind, controlled study to evaluate the efficacy and safety of intravenous VIS410 in addition to Oseltamivir (Tamiflu) compared with Oseltamivir alone in hospitalized adults with infulenza A infection requiring oxygen support. 

Principal Investigator(s): Stephen Ryan, MD

Study Coordinator: Jami Smith, [email protected], 253-403-0389

Pediatrics 

Idiopathic Bilateral Cataracts

CTX Prevelance Study

Study Number018CTXX15001—An observational, multicenter study of the prevelance of cerebrotendinous Xanthomatosis (CTX) in patient populations diagnosed with early-onset idiopathic bilateral cataracts.

Principal Investigator(s): Michael Raff, MD

Study Coordinator: Dalia Sherif, [email protected], 253-403-2698

Cystic Fibrosis

Non-interventional CF Study

Study NumberCTBM100C2407—A prospecitve observational study in cystic fibrosis patients with chronic respiratory Pseudomonas aeruginosa infection treated with TOBI Podhaler (tobramycin inhalation powder) or other FDA approved inhaled antipseudomonal antibacterial drugs.

Study Info

Principal Investigator(s): David Ricker, MD

Study Coordinator: Juanita Baker, [email protected], 253-403-3066